Huang, X.-W.; Zheng, H.-X.; Wang, M.-L.; He, W.-M.; Feng, M.-X.; Zeng, K.; Li, L.
Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines 2022, 10, 549.
https://doi.org/10.3390/vaccines10040549
AMA Style
Huang X-W, Zheng H-X, Wang M-L, He W-M, Feng M-X, Zeng K, Li L.
Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines. 2022; 10(4):549.
https://doi.org/10.3390/vaccines10040549
Chicago/Turabian Style
Huang, Xiao-Wen, Huan-Xin Zheng, Meng-Lei Wang, Wan-Mei He, Mei-Xin Feng, Kang Zeng, and Li Li.
2022. "Adalimumab in Treating Refractory Livedoid Vasculopathy" Vaccines 10, no. 4: 549.
https://doi.org/10.3390/vaccines10040549
APA Style
Huang, X.-W., Zheng, H.-X., Wang, M.-L., He, W.-M., Feng, M.-X., Zeng, K., & Li, L.
(2022). Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines, 10(4), 549.
https://doi.org/10.3390/vaccines10040549